Medable AI integrates genAI to streamline clinical trial startups, greatly reducing time to first patient enrollment.
Medable has introduced Medable AI, a GenAI-powered suite designed to speed up the clinical trial startup process for sponsors and CROs. Integrated into Medable Studio, this tool automates complex, manual trial setup tasks, significantly shortening the time to First Patient In (FPI). By leveraging genAI, Medable AI transforms workflows, enabling faster, more efficient development of digital and decentralized clinical trials.
Medable AI automates critical steps like creating electronic Clinical Outcome Assessments (eCOAs) from existing outcomes assessments in seconds. The tool’s ChatGPT-style interface simplifies editing and scaling assessments, a task that traditionally takes days but can now be completed within 30 minutes. This efficiency represents a breakthrough, aligning with Medable’s vision for rapid, one-day study startups and enhancing the ability of research teams to bring therapies to patients more quickly.
Beyond speed, Medable AI’s automated trial setup tools offer transparency and control, allowing researchers to adjust and track trial components more effectively. The platform’s scalable assessment generation and editing capabilities help teams manage diverse trial complexities, reducing bottlenecks and ensuring trials are ready to launch on schedule. This GenAI integration also enables more accessible trial builds, supporting Medable’s commitment to improving patient access to clinical trials.
Expected for general release in December 2024, Medable AI marks a significant step in Medable’s broader AI strategy to accelerate clinical trials. According to CEO Dr. Michelle Longmire, Medable AI represents “true innovation” in clinical development, with plans to further integrate AI to improve efficiency and patient outcomes across its platform.